e-Drug3D

1529

TAFLUPROST

INN
TAFLUPROST

(has an active metabolite)

cas 209860-87-7

CLASS

SENSORY
OPEN-ANGLE GLAUCOMA
OCULAR HYPERTENSION
PROSTAGLANDIN ANALOG
FP PROSTANOID RECEPTOR AGONIST

ROUTE (list)

OPHTHALMIC

ATC code

S01EE05

PK parameters

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET FP PROSTANOID RECEPTOR

DrugCentral

Prostaglandin F2-alpha receptor UNIPROT P43088 PTGFR

Download SDF file

1-methylethyl (5Z)-7-{(1R, 2R, 3R, 5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-butenyl}-3,5-dihydroxycyclopentyl]5-heptenoate

Formula:
C25H34F2O5

Calculated chemical properties:

MW 452.52
NB_atoms 32
XLogP 4.68
PSA 75.092
NB_HD 2
NB_HA 5
fsp3 0.56
Lipinski(0=no;1=yes) 1

FDA
NDA 202514 (label) INN (TAFLUPROST) ZIOPTAN (THEA PHARMA) APPROVAL= AP YEAR= 2012 NEWMOLECULARENTITY
NDA 209051 (pdf not found) INN (TAFLUPROST) TAFLUPROST (MICRO LABS) APPROVAL= AP YEAR= 2019
NDA 209040 (pdf not found) INN (TAFLUPROST) TAFLUPROST (SANDOZ) APPROVAL= AP YEAR= 2022
NDA 218002 (pdf not found) INN (TAFLUPROST) TAFLUPROST (INGENUS PHARMS LLC) APPROVAL= AP YEAR= 2024